Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.55 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.55 |
| ▸ | RELA | Q04206 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | CASP3 | P42574 | 1/20 | 0.55 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.55 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.55 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 4/20 | 0.47 |
| ▸ | CA12 | O43570 | 2/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | CA7 | P43166 | 2/20 | 0.47 |
| ▸ | CA9 | Q16790 | 2/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.47 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12500156 | 0.82 | NPC1 (0.57) | SMN1; SMN2MAPTNPC1RAB9ANFKB1 | |
| SCHEMBL1017506 | 0.81 | KDM4E (0.55) | MAPTNPC1RAB9ACASP3SENP8 | |
| SCHEMBL23554282 | 0.81 | MAPT (0.55) | SMN1; SMN2MAPTNPC1RAB9ANFKB1 | |
| SCHEMBL29549633 | 0.81 | MAPT (0.55) | SMN1; SMN2MAPTNPC1RAB9ANFKB1 | |
| SCHEMBL10464949 | 0.81 | NPSR1 (0.50) | SMN1; SMN2MAPTNPC1RAB9ANFKB1 | |
| Hydrochloric Acid SCHEMBL30639526 | 0.80 | KDM4E (0.54) | MAPTNPC1RAB9ACASP3SENP8 | |
| SCHEMBL4770167 | 0.79 | GABRP (0.65) | SMN1; SMN2MAPTNPC1RAB9ANFKB1 | |
| SCHEMBL21041119 | 0.79 | NNMT (0.69) | SMN1; SMN2MAPTNPC1RAB9ANFKB1 | |
| SCHEMBL22288456 | 0.79 | GAA (0.51) | SMN1; SMN2MAPTNPC1RAB9ANFKB1 | |
| SCHEMBL1246770 | 0.79 | SMN1; SMN2 (0.62) | SMN1; SMN2MAPTNPC1RAB9ANFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260015349-A1 | PROLYL HYDROXYLASE DOMAIN-CONTAINING PROTEIN (PHD) INHIBITORS AND USES THEREOF | INSILICO MEDICINE IP LTD (CN) | 2026-01-15 | — | — | US | disclosed |
| EP-3952870-B1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | NANJING ZENSHINE PHARMACEUTICALS CO LTD (CN) | 2025-09-24 | — | — | EP | disclosed |
| EP-3835300-B1 | 1,7-NAPHTHYRIDINE DERIVATIVE AND PREPARATION METHOD AND USE THEREFOR | CSPC ZHONGQI PHARMACEUTICAL TECH SHIJIAZHUANG CO LTD (CN) | 2025-02-19 | — | — | EP | disclosed |
| US-20250034132-A1 | PROLYL HYDROXYLASE DOMAIN-CONTAINING PROTEIN (PHD) INHIBITORS AND USES THEREOF | INSILICO MEDICINE IP LIMITED (HK) | 2025-01-30 | — | — | US | disclosed |
| US-12209101-B2 | Prolyl hydroxylase domain-containing protein (PHD) inhibitors and uses thereof | INSILICO MEDICINE IP LIMITED (HK) | 2025-01-28 | — | — | US | disclosed |
| EP-4423074-A1 | PROLYL HYDROXYLASE DOMAIN-CONTAINING PROTEIN (PHD) INHIBITORS AND USES THEREOF | Insilico Medicine IP Limited (HK) | 2024-09-04 | — | — | EP | disclosed |
| EP-4422623-A1 | PROLYL HYDROXYLASE DOMAIN-CONTAINING PROTEIN (PHD) INHIBITORS AND USES THEREOF | Insilico Medicine IP Limited (HK) | 2024-09-04 | — | — | EP | disclosed |
| CN-118591533-A | Prolyl hydroxylase domain-containing Protein (PHD) inhibitors and uses thereof | 英矽智能科技知识产权有限公司 | 2024-09-03 | — | — | CN | disclosed |
| US-12071443-B2 | Prolyl hydroxylase domain-containing protein (PHD) inhibitors and uses thereof | INSILICO MEDICINE IP LIMITED (HK) | 2024-08-27 | — | — | US | disclosed |
| CN-118488838-A | Prolyl hydroxylase domain-containing Protein (PHD) inhibitors and uses thereof | 英矽智能科技知识产权有限公司 | 2024-08-13 | — | — | CN | disclosed |
| EP-3952870-A1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | Nanjing Zhengxiang Pharmaceuticals Co., Ltd. (CN) | 2022-02-16 | — | — | EP | disclosed |
| CN-114025756-A | Phosphatidylinositol 3-kinase inhibitors | 南京征祥医药有限公司 | 2022-02-08 | — | — | CN | disclosed |
| US-20210332043-A1 | 1,7-NAPHTHYRIDINE DERIVATIVE AND PREPARATION METHOD AND USE THEREFOR | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD (CN) | 2021-10-28 | — | — | US | disclosed |
| US-20210332043-A1 | 1,7-NAPHTHYRIDINE DERIVATIVE AND PREPARATION METHOD AND USE THEREFOR | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD (CN) | 2021-10-28 | — | — | US | disclosed |
| EP-3835300-A1 | 1,7-NAPHTHYRIDINE DERIVATIVE AND PREPARATION METHOD AND USE THEREFOR | CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. (CN) | 2021-06-16 | — | — | EP | disclosed |
| CN-112689635-A | 1, 7-naphthyridine derivative and preparation method and application thereof | 石药集团中奇制药技术（石家庄）有限公司 | 2021-04-20 | — | — | CN | disclosed |
| WO-2020210379-A1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | HANGZHOU ZHENGXIANG PHARMACEUTICALS CO., LTD. (CN) | 2020-10-15 | — | — | WO | disclosed |
| CN-110878096-A | 1, 7-naphthyridine derivative and preparation method and application thereof | 石药集团中奇制药技术（石家庄）有限公司 | 2020-03-13 | — | — | CN | disclosed |
| US-20080200448-A1 | reversible and selective purinergic receptor P2Y12 antagonists; anticoagulants; cardiovascular disorders; e.g. ethyl 2-acetoxy-6-{4-[(benzylsulfonyl)carbamoyl]piperidin-1-yl}-5-cyanonicotinate | ASTRAZENECA AB (SE) | 2008-08-21 | — | — | US | disclosed |
| WO-2008085119-A1 | NEW PYRIDINE ANALOGUES VIII 518 | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260015349-A1 | PROLYL HYDROXYLASE DOMAIN-CONTAINING PROTEIN (PHD) INHIBITORS AND USES THEREOF | CBR1, HCCS, NCOR1 | SMN1; SMN2 4261/4885MAPT 4705/4885NPC1 953/4885 |
| US-20250034132-A1 | PROLYL HYDROXYLASE DOMAIN-CONTAINING PROTEIN (PHD) INHIBITORS AND USES THEREOF | EGLN3, EGLN2, EGLN1 | SMN1; SMN2 4522/4885MAPT 2807/4885NPC1 3553/4885 |
| US-20210332043-A1 | 1,7-NAPHTHYRIDINE DERIVATIVE AND PREPARATION METHOD AND USE THEREFOR | HIF1A, HIF1AN, P4HA1 | SMN1; SMN2 1686/4885MAPT 328/4885NPC1 314/4885 |
| US-12071443-B2 | Prolyl hydroxylase domain-containing protein (PHD) inhibitors and uses thereof | EGLN3, EGLN2, EGLN1 | SMN1; SMN2 4522/4885MAPT 2807/4885NPC1 3553/4885 |
| US-20080200448-A1 | reversible and selective purinergic receptor P2Y12 antagonists; anticoagulants; cardiovascular disorders; e.g. ethyl 2-acetoxy-6-{4-[(benzylsulfonyl)carbamoyl]piperidin-1-yl}-5-cyanonicotinate | P2RY12, P2RY13, P2RY11 | SMN1; SMN2 3460/4885MAPT 4725/4885NPC1 3540/4885 |
| US-12209101-B2 | Prolyl hydroxylase domain-containing protein (PHD) inhibitors and uses thereof | EGLN2, EGLN3, EGLN1 | SMN1; SMN2 3950/4885MAPT 4011/4885NPC1 2904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.